title: Lack of association between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals.
abstract: It is unknown whether favorable HLA class II alleles may attenuate HIV-1 through selection pressure in a manner similar to that of protective HLA class I alleles. We investigated the relationship between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals. No associations were found between individual alleles and lower replication capacity, suggesting no significant HIV-1 attenuation by HLA class II-restricted Gag-specific CD4(+) T cell immune pressure.
authors.affiliation: HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
authors.forename: Jaclyn K
authors.initials: JK
authors.lastname: Wright
authors.forename: Zabrina L
authors.initials: ZL
authors.lastname: Brumme
authors.forename: Boris
authors.initials: B
authors.lastname: Julg
authors.forename: Mary
authors.initials: M
authors.lastname: van der Stok
authors.forename: Zenele
authors.initials: Z
authors.lastname: Mncube
authors.forename: Xiaojiang
authors.initials: X
authors.lastname: Gao
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Carlson
authors.forename: Philip J R
authors.initials: PJ
authors.lastname: Goulder
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Walker
authors.forename: Mark A
authors.initials: MA
authors.lastname: Brockman
authors.forename: Thumbi
authors.initials: T
authors.lastname: Ndung'u
mesh_terms: D000483:Alleles; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology; D015658:HIV Infections / Q000235:genetics* / Q000276:immunology / Q000821:virology*; D015497:HIV-1 / Q000145:classification / Q000201:enzymology / Q000235:genetics / Q000502:physiology*; D015395:Histocompatibility Antigens Class I / Q000235:genetics* / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000235:genetics* / Q000276:immunology; D006801:Humans; D010447:Peptide Hydrolases / Q000235:genetics / Q000378:metabolism; D014779:Virus Replication; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D054301:gag Gene Products, Human Immunodeficiency Virus; D010447:Peptide Hydrolases
references.citation: Bone Marrow Transplant. 2010 May;45(5):846-8
references.pmid: 20348972
references.citation: Discov Med. 2010 Mar;9(46):261-6
references.pmid: 20350494
references.citation: Nat Rev Immunol. 2010 Jan;10(1):11-23
references.pmid: 20010788
references.citation: J Virol. 2010 Nov;84(22):11937-49
references.pmid: 20810731
references.citation: J Virol. 2009 Sep;83(17):8722-32
references.pmid: 19553327
references.citation: J Infect Dis. 2010 Oct 15;202 Suppl 2:S302-8
references.pmid: 20846037
references.citation: Nat Genet. 2007 Jun;39(6):733-40
references.pmid: 17496894
references.citation: Nat Immunol. 2004 Sep;5(9):927-33
references.pmid: 15300249
references.citation: J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):140-8
references.pmid: 16394844
references.citation: Nature. 2002 May 2;417(6884):95-8
references.pmid: 11986671
references.citation: PLoS Pathog. 2008 Mar 21;4(3):e1000033
references.pmid: 18369479
references.citation: J Virol. 2007 Nov;81(22):12608-18
references.pmid: 17728232
references.citation: Dis Markers. 2009;27(3):105-20
references.pmid: 19893207
references.citation: J Virol. 2010 Aug;84(15):7581-91
references.pmid: 20504921
references.citation: Annu Rev Med. 2003;54:535-51
references.pmid: 12525683
references.citation: J Virol. 2009 Sep;83(17):8916-24
references.pmid: 19515784
references.citation: J Exp Med. 1998 Nov 16;188(10):1785-93
references.pmid: 9815256
references.citation: J Exp Med. 2009 Apr 13;206(4):909-21
references.pmid: 19307327
references.citation: J Virol. 2009 Jan;83(1):140-9
references.pmid: 18971283
references.citation: J Virol. 2010 Oct;84(20):10820-31
references.pmid: 20702636
references.citation: J Infect Dis. 2011 Mar 15;203(6):803-9
references.pmid: 21257739
references.citation: J Virol Methods. 2006 Feb;131(2):134-42
references.pmid: 16182382
references.citation: Hum Immunol. 1997 Jul;55(2):154-62
references.pmid: 9361967
references.citation: PLoS Comput Biol. 2008 Nov;4(11):e1000225
references.pmid: 19023406
references.citation: J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):261-7
references.pmid: 18167642
references.citation: Nat Med. 1996 Apr;2(4):405-11
references.pmid: 8597949
references.citation: Rev Med Virol. 2005 Jul-Aug;15(4):219-33
references.pmid: 15942979
references.citation: J Clin Invest. 2001 Feb;107(4):505-17
references.pmid: 11181650
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
references.pmid: 12883005
references.citation: J Virol. 2006 Apr;80(7):3617-23
references.pmid: 16537629